Efficacy and safety analysis of upadacitinib in the treatment of moderate to severe inflammatory bowel disease
10.3969/j.issn.1672-2159.2024.08.007
- VernacularTitle:乌帕替尼治疗中至重度炎症性肠病的疗效和安全性分析
- Author:
Xiuli ZHU
1
;
Jiaqin XU
;
Qiaomin WANG
;
Li XIE
;
Xuemei XU
Author Information
1. 230002 中国科学技术大学附属第一医院(安徽省立医院)消化内科
- Keywords:
Upadacitinib;
Inflammatory bowel disease;
Ulcerative colitis;
Crohn's disease
- From:
Modern Interventional Diagnosis and Treatment in Gastroenterology
2024;29(8):917-922
- CountryChina
- Language:Chinese
-
Abstract:
Objective This study summarized the clinical data of IBD patients receiving upadacitinib treatment in our hospital,and provided more Chinese data to better guide the treatment of upadacitinib in Chinese IBD population.Methods Clinical data of 11 patients with IBD who received upadacitinib treatment at Anhui Provincial Hospital from March 1,2023 to September 8,2024 were retrospectively analyzed.Platelet count,ESR,CRP,disease severity score,endoscopic score,and adverse reactions were compared before treatment,at the 4th and 8th week of treatment,and clinical response rate,clinical response rate,endoscopic response rate,and endoscopic response rate were calculated.SPSS 25.0 software was used for statistical analysis.Results The platelets,ESR and CRP of patients at the 4th and 8th week after upadacitinib treatment were decreased compared with those before treatment,with statistical significance.At the 4th week,the clinical response rate was 72.72％(8/11),the clinical remission rate was 0,the clinical response rate of UC patients was 83.33％(5/6),and the clinical response rate of CD patients was 60％(3/5).At the 8th week of treatment,the clinical response rate was 100％(10/10),the clinical remission rate was 80.00％(8/10),the clinical response rate of UC patients was 100％(6/6),the clinical remission rate of UC patients was 83.33％(5/6),the clinical response rate of CD patients was 100％(4/4),and the clinical remission rate of CD was 75％(3/4).There were no adverse reactions during treatment.Three patients were re-examined by colonoscopy,all of whom were severe UC patients and achieved mucosal healing.Conclusion Upadacitinib can rapidly,effectively and sustainably control the disease in patients with moderate and severe IBD,with high safety.
